Background: Electronic prescribing (EP) and electronic hospital pharmacy (EHP) systems are increasingly common. A potential benefit is the extensive data in these systems that could be used to support antimicrobial stewardship, but there is little information on how such data are currently used to support the quality and safety of antimicrobial use.
Introduction
Increasing antimicrobial resistance is a global phenomenon, mainly attributable to increases in antimicrobial consumption in human, veterinary and agricultural sectors. Public health bodies worldwide advocate the use of antimicrobial stewardship programmes as a strategy to help combat antimicrobial resistance and curb the selection and proliferation of resistant microorganisms. Monitoring antimicrobial consumption is a key component of these strategies. [1] [2] [3] [4] The UK Five Year Antimicrobial Resistance Strategy 2013 to 2018 5 lists seven key areas that need to be addressed to tackle the burden of antimicrobial resistance, one of which, 'optimising prescribing practice', includes as a priority 'identifying the optimum arrangements for recording and reporting of data (including the use of electronic prescribing), as well as analysis of data on antibiotic use, resistance and clinical outcomes'. Other large-scale antimicrobial stewardship programmes in the USA and the UK similarly promote the use of information technology to help monitor antimicrobial usage. 1, 6 V C The Author 2017. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For Permissions, please email: journals.permissions@oup.com.
A potential benefit of both electronic prescribing (EP) and electronic hospital pharmacy (EHP) systems is that data on medication use are recorded as part of the system, creating the potential for secondary use of data (SuD) to understand, monitor and subsequently improve antimicrobial use. Although likely to support antimicrobial stewardship, little is known about the extent to which this potential benefit has been realized. Previous systematic reviews have focused on the benefits of using EP to reduce medication errors and adverse drug events [7] [8] [9] [10] and on the use of clinical decision support systems (CDSSs) to support antibiotic use.
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A more recent review focused on the effectiveness of information technology in general in improving hospital antimicrobial prescribing, but did not specifically include SuD. 12 Another focused on hospital EP systems in promoting appropriate use of antibiotics, but examined only experimental studies published since 1997, most of which involved prompts and reminders aimed at individual patient care. 13 The authors of that study specifically highlight the need to more thoroughly explore interventions that draw on SuD as these are likely to present the biggest returns on investment. 13 No systematic review has explored the use of data from EP and EHP systems for antimicrobial stewardship.
Our objectives were to review the literature on SuD from EP and EHP systems to support quality and safety of antimicrobial use in the hospital setting, to describe any barriers to secondary use and to make recommendations for future work in this field.
Methods

Search strategy
Our search strategy was based on four facets: (1) electronic data systems and surveillance; (2) anti-infectives; (3) quality and safety; and (4) hospitals. Following piloting of the sensitivity and specificity of various search strategies, we used Medical Subject Headings and keywords for each of the four facets based on the following Boolean logic: [1 AND 2 AND (3 OR 4)] OR ('secondary use adj4 data'). The final search term was used to help capture articles that focused on SuD, but may not have included the other search terms.
One researcher (N. T. C.) conducted the search on 15 August 2014 using the following databases: International Pharmaceutical Abstracts, Cumulative Index to Nursing and Allied Health Literature, Medline and Excerpta Medica (Embase). The full search strategies used for each database are provided in Table S1 (available as Supplementary data at JAC Online).
Inclusion and exclusion criteria
We defined SuD as 'the reuse of aggregated electronic (clinical or operational) data from an EP or EHP system for purposes other than direct patient care or for its original purpose' (N. T. Chaudhry, B. D. Franklin, S. Mohammad and J. Benn, unpublished data).
We included any original research based on SuD from EP and/or EHP systems that included antimicrobial data and reported safety and/or quality outcomes relating to antimicrobials and/or qualitative findings relating to SuD, in the hospital setting. We were primarily interested in evidence supporting the effectiveness of interventions based on SuD, but also more broadly in how data from EP and EHP systems were being used to support antimicrobial stewardship. Reviews, conference proceedings, letters and opinion papers were excluded, as were studies based on paper-based prescribing or databases other than EP or EHP. There were no limits by study design, year or country. Table S2 presents full inclusion and exclusion criteria.
Study selection
One researcher (C. M.) screened titles and abstracts (or titles only if abstracts were unavailable) to identify those for potential inclusion. A sample of the titles and abstracts (n " 50) was then screened by second (N. T. C.) and third (B. D. F.) reviewers and any disagreements were resolved through discussion. For final study selection, the full-text papers were assessed by the primary reviewer (C. M.) and those recommended for inclusion, plus any for which there was any uncertainty, were screened independently by N. T. C. and B. D. F. Reference lists of full-text papers selected for inclusion were screened to identify any further eligible studies.
Data extraction and analysis
An electronic data collection form was completed by C. M. for each included study. Extracted data comprised: data collection period, country and setting, type of study, aim/objectives, EP/EHP system, how the data were extracted and used, methods and main outcomes. Data from each study were then extracted to inform a descriptive analysis; the anticipated heterogeneity of the studies precluded meta-analysis. In addition, any reported barriers to effective SuD were documented. Data extraction was checked by B. D. F. and any discrepancies were resolved via discussion.
The review was conducted and reported according to the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) guidelines. 14 The protocol was registered with the PROSPERO international prospective register of systematic reviews (registration CRD42016042955).
Results
Initial screening of titles and abstracts yielded 233 records from a total of 2331 de-duplicated titles/abstracts. Following review by N. T. C. and B. D. F., 92 were identified for full-text review. Full-text screening of these 92 papers resulted in 12 that met our inclusion criteria. Reasons for exclusion are provided in Figure 1 . Two further studies were identified from manual review of reference lists, giving a total of 14 included studies (Table S3) .
Characteristics of included studies
Of the 14 studies, only 2 described interventions based on SuD: 15, 16 1 was an uncontrolled before-and-after evaluation of an antimicrobial audit and feedback intervention and 1 tested four sequential interventions, one of which involved real-time clinical data dashboards, using interrupted time series analysis (also based on SuD). Seven described the reuse of EP/EHP data to evaluate other interventions [17] [18] [19] [20] [21] [22] [23] and five described descriptive or exploratory studies of SuD. [24] [25] [26] [27] [28] Of the seven evaluative studies, one evaluated a randomized controlled trial, 17 three were uncontrolled before-and-after studies, [18] [19] [20] two were time series studies 16, 23 and one was a descriptive evaluation. 21 We did not identify any qualitative studies that met our inclusion criteria.
The majority of studies (eight) [17] [18] [19] [20] [21] [22] 25, 26 were conducted in the USA. Three were from the UK 16, 23, 27 and one each from Germany, 24 South Korea 28 and Australia. 15 The majority (11) were single-centre studies. [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] 28 Three specifically focused on paediatric hospitals. 19, 20, 25 
Types of data used
Most studies included only antimicrobials; three included other drugs, but separately reported antimicrobials. 16, 21, 28 There was wide heterogeneity between studies in how data were generated Systematic review JAC and from which systems (Table S3 ). Ten used data from EP systems, one from an EHP system and three from both. Of the 14 studies, 4 combined data from EP and/or EHP systems with other electronic data: from the hospital information system, 18,28 laboratory system 25, 28 and an automated dispensing machine. 18 Two further studies additionally used data from handwritten records. 15, 22 The types of data used fell into three categories: (1) antibiotic prescribing or usage data (nine studies); (2) dose administration data (four studies); and (3) user log data (one study).
Antibiotic usage data
One of the two interventions based on SuD was an Australian study 15 that used data generated from an EP system to audit doctors' antimicrobial prescribing choices according to local guidance and provide feedback to prescribers; the study did not reveal any significant change in prescribing practice. Others used EP and/or EHP systems to obtain data such as numbers of antimicrobial medication orders, dispensing volumes, course durations and doses, either to evaluate interventions (all US studies) [17] [18] [19] [20] or to explore the use of the data for benchmarking or quality improvement, with studies from the USA, 25, 26 Germany 24 and South Korea. 28 
Dose administration data
The second study that evaluated an SuD intervention was a UK study of four sequential interventions, one of which involved a real-time dashboard showing omission rates for antibiotics, nonantibiotics and dietary supplements, plus weekly feedback e-mails. Introduction of the dashboard was associated with a significant reduction in the level (P " 0.001) and trend (P , 0.001) for antibiotic dose omission rates, using segmented regression analysis. 16 A second UK study used EP data to explore use of antimicrobial dose omission data for benchmarking among hospitals. 27 Two further studies focused on delays in dose administration and evaluated interventions to reduce time to administration of MRSAdecolonizing therapy in a UK hospital 23 and to reduce time to first dose of intravenous antimicrobials in a US hospital. 22 User log data A US study 21 made use of user log data to evaluate how real-time surveillance dashboards for high-risk medications (including aminoglycosides) were being used by pharmacists to inform clinical practice.
Barriers
Several studies 15, 21, 22, 24, [26] [27] [28] suggested that data extraction was sometimes a complex or tedious process, often requiring informatics specialists, and that quality and completeness of information input into electronic systems was critical. 15, 21, 24, 25 The available data may not include all the information required, such as data required to assess outcomes or appropriateness. 16, 17, 24 Authors noted that systems were often localized and so studies may not be generalizable to other hospital settings. 21, 23 Two studies took Full-text articles assessed for eligibility (n = 92)
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Systematic review place across multiple sites with different EP systems; this contributed to increased complexity and additional data validation requirements. 26, 27 Baysari et al. 15 specifically recommended that vendors of EP systems could do more to facilitate generation of SuD from their systems.
Discussion
Key findings
We identified 14 relevant studies, only 2 of which described interventions based on SuD. 15, 16 Others were descriptive or exploratory studies of SuD or used SuD to evaluate other interventions and suggest potential benefits in using such large datasets. Studies suggest that data extraction from EP and EHP was not straightforward, may require linkage of data from more than one system and may be further limited by the quality of clinical information entered.
Comparison with previous literature
Previous ethnographic research 29, 30 has studied SuD for the purposes of driving improvements in quality and safety in healthcare more generally. One paper 29 describes a study of an organization that used SuD from an EP system to obtain real-time information on a variety of quality indicators and generate intelligence on performance of individuals, teams and clinical services, as well as to identify and evaluate interventions. Measures such as the prevalence of omitted doses showed marked improvement. Potential unintended consequences were identified, including the risk of focusing attention on aspects of patient safety made visible by the system at the expense of less measurable issues. This issue was not identified in our review, most likely due to different types of SuD and lack of studies using qualitative methods. A second study 30 identified that extra work was required for SuD, with ambiguity over who should be responsible for this extra work. While we identified that generation of useful data requires significant investment, appropriate infrastructure and dedicated informatics specialists, ambiguity around responsibility was not specifically identified, again likely to reflect the types of study included.
Strengths and limitations
Strengths include use of a systematic approach, 14 including independent review of each stage of screening and data extraction. Limitations include the wide range of terms used in relation to SuD; this may account for two of the included studies 17, 22 being identified from reference lists of other publications and it is therefore possible that we missed further papers in our search. Other studies included insufficient detail as to how data were generated and had to be excluded. [31] [32] [33] International variation in terminology and practice around EP and EHP systems also introduced challenges in interpreting the literature, although we believe we were able to address these through the combined experience of our team. We did not formally assess risk of bias in included studies due to the heterogeneous nature of included studies and the paucity of interventions based on SuD. We did not identify any qualitative studies that met our inclusion criteria.
Implications for practice
National Institute for Health and Care Excellence (NICE) guidance on antimicrobial stewardship, 34 which applies to England and Wales, lists EP as a specific area needed to drive quality improvement. Our work has identified that data suitable for secondary use are currently being generated from EP (and EHP) systems in hospital settings and are being used to identify areas for quality improvement and to monitor the impact of antimicrobial stewardship initiatives. However, the best approaches to SuD are not yet clear. While the primary functions of EP/EHP systems receive considerable attention from vendors and implementation teams, the difficulties and challenges that some authors report in obtaining data for secondary use highlight the need for potential secondary uses to be considered. Data quality at point of input also constrains downstream opportunities for effective SuD, suggesting a need for local commitment to accurate data entry and quality assurance. Adequate investment in health service infrastructure (including informatics specialists) is required, with consideration to a whole healthcare economy approach. This may include linkage with other systems to aid assessment of antimicrobial choice.
Implications for research
We found that there is a lack of robust evidence around SuD as an intervention to improve antimicrobial stewardship; we found only two studies that tested intervention based on SuD, one of which demonstrated benefits in the outcome measure assessed 16 and one of which did not. 15 There is therefore an urgent need for the public health and research community to target this topic, as currently very little information is available to help define, develop and implement interventions using SuD. Future evaluation of SuD interventions should include use of qualitative and mixed methods designs, in order to understand mechanisms and processes governing effective reuse of data, including enablers as well as barriers and the effects of local organizational context, in addition to impact upon outcomes.
Conclusions
Our study suggests that the current paucity of evaluative interventional evidence may be due to immaturity in secondary use functions in current systems, which in turn hinders replication and evaluation of SuD for antimicrobial stewardship. SuD from EP and EHP systems may be useful to support or evaluate antimicrobial stewardship interventions in hospital settings. However, SuD is often a complex process, especially where multiple systems are used, necessitating informatics specialists and careful consideration of data quality. Greater system functionality may also help realize the benefits. Studies of antimicrobial stewardship interventions based on SuD are lacking, representing a key area where future research is needed.
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